Phase II Trial of Alisertib (MLN8237) in Salvage Malignant Mesothelioma

Trial Profile

Phase II Trial of Alisertib (MLN8237) in Salvage Malignant Mesothelioma

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 20 Feb 2017

At a glance

  • Drugs Alisertib (Primary)
  • Indications Mesothelioma
  • Focus Therapeutic Use
  • Most Recent Events

    • 15 Feb 2017 Planned End Date changed from 1 Feb 2021 to 1 May 2021.
    • 15 Feb 2017 Status changed from recruiting to active, no longer recruiting.
    • 20 May 2015 Planned primary completion date changed from 1 Feb 2021 to 1 May 2021 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top